Gene · 10643
Papers3,038
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,081 to 1,100 of 3,038
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Development and validation of a prognostic model related to pyroptosis-related genes for esophageal squamous cell carcinoma using bioinformatics analysis. | J Thorac Dis | 2022 | 36071753 | PubTator, text mining | PubMed |
| Targeting RNA N6-methyladenosine modification: a precise weapon in overcoming tumor immune escape. | Mol Cancer | 2022 | 36071523 | PubTator, text mining | PubMed |
| 3D chromatin maps of the human pancreas reveal lineage-specific regulatory architecture of T2D risk. | Cell Metab | 2022 | 36070683 | PubTator, text mining | PubMed |
| Tagged actin mRNA dysregulation in IGF2BP1[Formula: see text] mice. | Proc Natl Acad Sci U S A | 2022 | 36067310 | PubTator, text mining | PubMed |
| CPEB2 m6A methylation regulates blood-tumor barrier permeability by regulating splicing factor SRSF5 stability. | Commun Biol | 2022 | 36064747 | PubTator, text mining | PubMed |
| Integrated risk scores from N6-methyladenosine-related lncRNAs are potential biomarkers for predicting the overall survival of bladder cancer patients. | Front Genet | 2022 | 36061188 | PubTator, text mining | PubMed |
| Integrated pan-cancer analysis of CSMD2 as a potential prognostic, diagnostic, and immune biomarker. | Front Genet | 2022 | 36061177 | PubTator, text mining | PubMed |
| LINC00887 Fosters Development of Clear Cell Renal Cell Carcinoma via Inhibiting CD8+ T Cell Immune Infiltration. | Comput Math Methods Med | 2022 | 36060659 | PubTator, text mining | PubMed |
| Gene signatures, immune infiltration, and drug sensitivity based on a comprehensive analysis of m6a RNA methylation regulators in cervical cancer. | J Transl Med | 2022 | 36058934 | PubTator, text mining | PubMed |
| Suppression of ACE2 SUMOylation protects against SARS-CoV-2 infection through TOLLIP-mediated selective autophagy. | Nat Commun | 2022 | 36057605 | PubTator, text mining | PubMed |
| The function and regulatory mechanism of RNA-binding proteins in breast cancer and their future clinical treatment prospects. | Front Oncol | 2022 | 36052258 | PubTator, text mining | PubMed |
| Effects of N6-Methyladenosine Regulators on LAG3 and Immune Infiltrates in Lung Adenocarcinoma. | Dis Markers | 2022 | 36051357 | PubTator, text mining | PubMed |
| Comprehensive analyses of N6 -methyladenosine-related long noncoding RNA profiles with prognosis, chemotherapy response, and immune landscape in small cell lung cancer. | Cancer Sci | 2022 | 36047973 | PubTator, text mining | PubMed |
| The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells. | Sci Signal | 2022 | 36041010 | PubTator, text mining | PubMed |
| Comprehensive analysis of molecular features, prognostic values, and immune landscape association of m6A-regulated immune-related lncRNAs in smoking-associated lung squamous cell carcinoma. | Front Genet | 2022 | 36035178 | PubTator, text mining | PubMed |
| m6A regulator-based methylation modification patterns and characterization of tumor microenvironment in acute myeloid leukemia. | Front Genet | 2022 | 36035161 | PubTator, text mining | PubMed |
| Non-coding RNAs in skin cancers:Biological roles and molecular mechanisms. | Front Pharmacol | 2022 | 36034860 | PubTator, text mining | PubMed |
| Novel insight into m6A regulator-mediated methylation modification patterns and immune characteristics in intracranial aneurysm. | Front Aging Neurosci | 2022 | 36034129 | PubTator, text mining | PubMed |
| Allosteric Regulation of IGF2BP1 as a Novel Strategy for the Activation of Tumor Immune Microenvironment. | ACS Cent Sci | 2022 | 36032766 | PubTator, text mining | PubMed |
| Identification and Validation of an m6A-Related LncRNA Signature to Predict Progression-Free Survival in Colorectal Cancer. | Pathol Oncol Res | 2022 | 36032659 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/10643/papers?page=55